Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial - Robson, M; Ruddy, K J; Im, S A (Eur J Cancer, 2019)